Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics’ pancreatic cancer a bust

Incyte meets endpoint in the second pivotal atopic dermatitis clinical trial

A second phase 3 trial of Incyte’s ruxolitinib cream in atopic dermatitis has hit its primary endpoint. The back-to-back pivotal successes irked Incyte to talk to regulators regarding upcoming of the JAK inhibitor to market.

Ruxolitinib is the small molecule JAK1/2 inhibitor found in Jakafi, for myelofibrosis treatment of Incyte. Incyte has placed itself to produce more cash from the molecule by positioning it as an atopic dermatitis treatment option for patients.

Lately, Incyte has shown top-line data from the second phase 3 trial. The second trial also hit its primary endpoint, with more than 50% of patients on the higher dose of ruxolitinib reaching success on an investigator assessment when compared to 8% in the placebo group.

NeoTX Therapeutics lands USD 45 Million series C for combo I-O cancer trials

NeoTX Therapeutics, a biopharmaceutical company developing cancer immunotherapies. The company has landed a boastful of USD 45 million third funding round as it is up for continuing work on its early-stage cancer combo test and in-license new tech.

NeoTX is leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies.  

The Rehovot, Israel-based biotech is actively working on a Selective T cell Redirection (STR) platform for its oncology immunotherapies, and now its total funding draws to USD 60 million.

A combo of the pancreatic cancer of Five Prime Therapeutics with Opdivo a bust

Five Prime Therapeutics, a clinical-stage biotechnology company, aimed at discovering and developing innovative therapeutics to improve the lives of patients with serious diseases.

Pancreatic cancer is a severe disease to treat. Unfortunately, the combination of Five Prime Therapeutics’ experimental CSF-1 receptor inhibitor cabiralizumab and Bristol-Myers Squibb’s checkpoint inhibitor Opdivo, with and without chemotherapy did not display any fruitful benefit over standard of care chemotherapy in this randomized, controlled phase 2 trial.

Pancreatic cancer has one of the lowest success rates lately among the biopharma oncology trials and is often detected late in the disease, with a very high level of mortality.